创新药概念持续活跃 百济神州等多股创历史新高 智通财经4月30日电，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制 药、华东医药、恒瑞医药等涨幅靠前。消息面上，2025年一季度，已经出现了超20笔涉及中国药企全球 授权的交易，BD交易有望在今年再创新高。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000963 证券简称：华东医药 公告编号：2025-038 华东医药股份有限公司 关于举办投资者接待日活动的公告 华东医药股份有限公司（以下简称"公司"）2024年年度报告已于 2025年4月18日发布，2025年第一季度报告于2025年4月25日发布，为 增进与投资者交流，使广大投资者更深入、全面地了解公司发展战略、 经营成果、财务状况，公司将举办投资者接待日活动，现将有关事项 公告如下： 一、会议时间、地点和形式 1、接待日：2025年5月15日（星期四）。 2、接待时间：2025年5月15日下午15:30-17:00，即公司2024年度 股东大会现场投票结束后，在股东大会会场举行投资者接待日活动。 3、召开形式：现场参与。会场设在公司会议室（浙江省杭州市 拱墅区莫干山路858号华东医药股份有限公司新大楼3楼远大厅）。 4、预约登记： 参与本次活动的投资者，请扫描以下二维码，进行报名，报名截 止时间为2025年5月14日（星期三）15:00。逾期报名的投资者将不便 安排，欢迎参与公司下次召开的活动 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-037 华东医药股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华东医药股份有限公司（以下简称"公司"）已于 2025 年 4 月 18 日在《中国证券报》《上海证券报》《证券时报》和巨潮资讯网 （www.cninfo.com.cn）刊登了《华东医药股份有限公司关于召开 2024 年度股东大会的通知》（公告编号：2025-033）。现发布提示性公告， 并将有关事项再次通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会。 2、股东大会的召集人：公司董事会 公司于 2025 年 4 月 16 日召开的第十届董事会第三十二次会议 审议通过了《关于召开 2024 年度股东大会的议案》，决定召开 2024 年度股东大会。 3、会议召开的合法、合规性：本次股东大会的召开符合有关法 律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则及 《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 ...

二〇二四年度股东大会 会 议 材 料 （000963.SZ） 二〇二五年五月十五日 1 大会须知 为充分尊重广大股东的合法权益，确保本次股东大会的顺利进行， 根据《公司法》、《公司章程》以及《股东大会议事规则》等有关规定， 现就本次会议的注意事项及会务安排通报如下： 一、公司股东大会不安排现场参观。 二、公司 2024 年度股东大会所有提案，股东及股东代表以记名 方式分别表决。 三、每一表决票分别注明所代表的股权数，每股为一票表决权， 投票结果按股权数判定票数。 四、提案 8.00《关于 2025 年度日常关联交易预计的议案》，关联 股东需回避表决，且回避该提案表决的同时不可接受其他股东的委托 进行投票。 五、本次表决由监票员、计票员执行各项有关事宜，并宣布表决 结果。 六、表决时，参加股东大会现场会议的股东应当在表决票中提案 对应的"同意""反对""弃权"栏目进行勾选。表决票签字有效。 七、不使用本次会议统一发放的表决票，或夹写规定以外的文字 或表决意向填写模糊无法辨认者视为无效票。 八、本次大会特邀请浙江天册律师事务所律师对大会的全部议程 进行见证。 2 华东医药股份有限公司 2024 年度股东大会会议议 ...

Group 1 - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7459.13 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 3.80% over the past month, increased by 3.37% over the past three months, and has risen by 0.20% year-to-date [1] - The CSI 300 Index categorizes its 300 sample stocks into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (24.67%), WuXi AppTec (16.06%), Pian Zai Huang (6.84%), Yunnan Baiyao (5.71%), Kelun Pharmaceutical (4.69%), New Horizon (3.81%), East China Pharmaceutical (3.6%), Shanghai Raist (3.44%), Fosun Pharma (3.37%), and Changchun High-tech (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.43% from the Shanghai Stock Exchange and 36.57% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: chemical drugs (42.67%), pharmaceutical and biotechnology services (21.27%), traditional Chinese medicine (19.68%), and biological drugs (16.38%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the sample adjustments, which are generally fixed until the next scheduled adjustment [2] - Temporary adjustments occur when the CSI 300 Index samples are modified, and changes in industry classification due to special events will also lead to corresponding adjustments in the CSI 300 industry index [2]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [4]. Core Viewpoints - The domestic weight loss drug market is entering commercialization, emphasizing the importance of sales capabilities for companies [1][19]. - The competition in the global weight loss drug market is intensifying, particularly between Novo Nordisk and Eli Lilly, where marketing strategies play a crucial role in sales performance [19][23]. - Companies with advanced R&D progress and strong sales execution will hold competitive advantages in the commercialization phase of weight loss drugs [1][19]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 1.16%, outperforming the CSI 300 index by 0.77 percentage points but underperforming the ChiNext index by 1.08 percentage points, ranking 15th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Healthcare Index increased by 8.44%, outperforming the Hang Seng Index by 6.12 percentage points [1][15]. Company Updates - Recent clinical application updates include Baiyi Shenzhou's injection BGB-B2033 and Nuo Cheng Jian Hua's injection ICP-B794, both newly undertaken [27]. - Ongoing clinical trials include Bo Rui Pharmaceutical's BGM0504 and Hua Dong Pharmaceutical's HDM1002, currently in Phase III [27]. Investment Strategy - The report suggests a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: in-hospital payments, out-of-pocket payments, and overseas payments [2]. - Key recommended companies include Heng Rui Pharmaceutical, Mai Rui Medical, and United Imaging Healthcare [2]. Company Profit Forecasts and Valuation - Heng Rui Pharmaceutical is rated "Accumulate" with a projected EPS of 0.99 yuan for 2024 and a PE ratio of 51 [3]. - Mai Rui Medical is rated "Buy" with a projected EPS of 11.47 yuan for 2024 and a PE ratio of 19 [3]. - United Imaging Healthcare is also rated "Buy" with a projected EPS of 2.88 yuan for 2024 and a PE ratio of 44 [3].

Core Points - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7479.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 0.64% in the past month, increased by 3.66% over the last three months, and has risen by 0.48% year-to-date [1] Industry Composition - The CSI 300 Pharmaceutical and Biotechnology Index is composed of 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] - The index is based on the performance of all securities in the CSI 300 Index classified by industry, with a base date of December 31, 2004, and a base point of 1000.0 [1] Index Holdings - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: - Heng Rui Medicine (24.75%) - WuXi AppTec (15.82%) - Pian Zai Huang (6.85%) - Yunnan Baiyao (5.7%) - Kelun Pharmaceutical (4.68%) - New Horizon (3.79%) - East China Pharmaceutical (3.64%) - Shanghai Raist (3.44%) - Fosun Pharma (3.38%) - Changchun High-tech (3.17%) [1] Market Distribution - The market distribution of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.33% and the Shenzhen Stock Exchange accounts for 36.67% [2] Sector Breakdown - The sector breakdown of the index holdings indicates that: - Chemical drugs account for 42.69% - Pharmaceutical and biotechnology services account for 21.06% - Traditional Chinese medicine accounts for 19.74% - Biological drugs account for 16.51% [2] Sample Adjustment - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with sample changes, and any special events affecting a sample company's industry classification will lead to corresponding adjustments in the index [2]

证券代码：000963 证券简称：华东医药 华东医药股份有限公司投资者关系活动记录表 12.29%，环比2024年第四季度增长24.37%，整体经营符合第一季度计 划目标。国内医美全资子公司欣可丽美学积极拓展国内市场，报告期 内实现营业收入2.54亿元，同比下降1.36%，环比2024年第四季度增长 10.64% 。公司持续深化国内高端医美产品布局，高端玻尿酸 MaiLi®Extreme（商品名：魅俪®朔盈®）将于2025年5月正式实现商业化 销售；多功能面部皮肤管理平台Préime DermaFacial也将于2025年内正 式实现商业化销售。此外，重组A型肉毒毒素YY001、能量源设备V30 及Ellansé®伊妍仕®M型等核心医美产品国内上市申请均已获受理，有 望于2026年获批。依托国内差异化医美产品矩阵的持续丰富，叠加消 费升级带来的市场需求扩容，公司国内医美业务成长潜能将加速释放。 编号：2025-002 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □业绩说明会 □媒体采访 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 ☑其他 ...

Core Viewpoint - The company reported a stable growth in revenue and net profit for the first quarter of 2025, with significant contributions from its core subsidiaries and innovative drug sales, despite facing challenges in the medical aesthetics sector [6][10]. Financial Performance - The company achieved operating revenue of 10.736 billion yuan, a year-on-year increase of 3.12% and a quarter-on-quarter increase of 2.95% [6]. - The net profit attributable to shareholders was 915 million yuan, up 6.06% year-on-year, while the net profit excluding non-recurring gains and losses reached 897 million yuan, marking a historical high with a 7.04% increase year-on-year [6]. - The core subsidiary, China Medical East, reported operating revenue of 3.621 billion yuan, a 6.52% increase year-on-year, and a net profit of 843 million yuan, up 12.20% [7]. Business Segments - The pharmaceutical segment showed strong performance with innovative drug sales driving growth, particularly the CAR-T product and biosimilar drugs, which have gained significant market traction [7][8]. - The medical aesthetics segment faced challenges due to economic conditions and increased competition, with revenue from the UK subsidiary Sinclair declining by 12.29% year-on-year [10]. - The industrial microbiology segment experienced rapid growth, with a year-on-year increase of 29.98% [11]. R&D Progress - The company increased its R&D investment to 880 million yuan, a 49.60% year-on-year rise, with direct R&D expenses reaching 600 million yuan, up 71.77% [12]. - Significant milestones were achieved in the development of innovative drugs, including approvals and clinical trials for various oncology and metabolic disease treatments [12][15]. Market Expansion - The company is actively expanding its market presence, with over 70 insurance plans covering its CAR-T product, which is expected to sustain high growth [7]. - The acquisition of Guizhou Hengba Pharmaceutical has shown promising results, with revenue exceeding 24.26 million yuan and net profit of 6.67 million yuan in the reporting period [8].

Group 1: Aier Eye Hospital - In 2024, Aier Eye Hospital achieved an outpatient volume of 16.94 million, a year-on-year increase of 12.14% [1] - The company reported a total revenue of 20.98 billion yuan, reflecting a growth of 3.02% compared to the previous year [2] - The net profit attributable to shareholders was 3.56 billion yuan, up by 5.87% year-on-year [2] - The company introduced several advanced medical technologies and products, including the INTENSITY™ intraocular lens and new dry eye treatment technology [1][3] Group 2: Tonghuashun - Tonghuashun reported a revenue of 4.19 billion yuan in 2024, marking a 17.47% increase from the previous year [5] - The net profit attributable to shareholders reached 1.82 billion yuan, a significant growth of 30% year-on-year [4][5] - The increase in revenue and profit was primarily driven by a recovery in the securities market and rising demand for financial information services [4] Group 3: Yiwei Lithium Energy - Yiwei Lithium Energy achieved a revenue of 1.28 billion yuan in Q1 2025, with a net profit of 110.11 million yuan, reflecting a 16.60% increase in net profit [7] - The company reported a significant increase in the shipment of energy storage batteries, with a year-on-year growth of 80.54% [8] - The company is expanding into emerging markets such as eVTOL and drones, with ongoing projects and production facilities being established [9] Group 4: Huadong Medicine - Huadong Medicine reported a revenue of 10.74 billion yuan in Q1 2025, a 3.12% increase year-on-year [10] - The net profit attributable to shareholders was 914.71 million yuan, up by 6.06% compared to the same period last year [11] - The company achieved its highest historical level of net profit excluding non-recurring gains and losses, reaching 897.34 million yuan [10] Group 5: Muyuan Foods - Muyuan Foods reported a revenue of 36.06 billion yuan in Q1 2025, a year-on-year increase of 37.26% [17] - The company turned a profit with a net profit of 44.91 billion yuan, compared to a loss of 23.79 billion yuan in the same period last year [18] - The significant growth was attributed to increased pig prices and sales [17] Group 6: China Aluminum - China Aluminum reported a revenue of 55.78 billion yuan in Q1 2025, with a net profit of 3.54 billion yuan, reflecting a year-on-year increase of 58.78% [21] - The company successfully managed market price fluctuations, resulting in increased product sales and profits [21] Group 7: Hengrui Medicine - Hengrui Medicine achieved a revenue of 72.06 billion yuan in Q1 2025, a 20.14% increase year-on-year [22] - The net profit attributable to shareholders was 18.74 billion yuan, up by 36.9% compared to the previous year [22] - The increase in profit was significantly influenced by a licensing payment received during the reporting period [22] Group 8: Bull Group - Bull Group reported a revenue of 16.83 billion yuan in 2024, reflecting a 7.24% increase year-on-year [13] - The net profit attributable to shareholders was 4.27 billion yuan, a growth of 10.39% compared to the previous year [13] - The company experienced growth in its electrical connection and smart lighting businesses, as well as rapid development in its new energy sector [14]